Will nanobiosensors change therapeutic drug monitoring? The case of methotrexate.
Département de chimie, Université de Montréal, CP 6128 Succ. Centre-Ville, Montréal, QC, H3C 3J7, Canada.
Jean-Francois
JF
Masson
Joelle N
JN
Pelletier
D000964:Antimetabolites, Antineoplastic / Q000097:blood*; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D008727:Methotrexate / Q000097:blood*; D036103:Nanotechnology; D009369:Neoplasms / Q000188:drug therapy*; D020349:Surface Plasmon Resonance / Q000379:methods*
D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate
SPR; cancer treatment; medical laboratory; methotrexate; nanobiosensors; regulatory clearance; surface plasmon resonance; therapeutic drug monitoring